A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder

- Participants were men and women - between the ages of 18 and 65 - with Body Mass Index (BMI) <45 kg/m2 - who met DSM-IV criteria for BED

- Participants were excluded - for blood pressure >140/90 mm Hg - with pulse >95 beats/min - history of stroke, narrow angle glaucoma, cardiac disease, seizures, renal or hepatic dysfunction - use of insulin, medications known to affect body weight, or certain psychoactive medications (monoamine oxidase inhibitors, lithium, SSRIs, opioids) - current participation in a weight loss program - surgical treatment for obesity - bulimia nervosa or purging in the past 6 months - alcohol or drug abuse in the past 12 months - current psychiatric condition being treated with a psychoactive agent - current major depressive disorder - history of anorexia nervosa, psychosis, bipolar disorder, or suicide attempts - psychotherapy within the previous 2 months - Women were excluded if they were pregnant, lactating, or if fertile, not practicing adequate contraceptive precautions